NeuroSense Therapeutics (NeuroSense Therapeutics) EV-to-EBIT : 0.00 (As of Jun. 06, 2024)

View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NeuroSense Therapeutics's Enterprise Value is $0.00 Mil. NeuroSense Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.27 Mil. Therefore, NeuroSense Therapeutics's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for NeuroSense Therapeutics's EV-to-EBIT or its related term are showing as below:

NRSNW' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.75 Med: 0 Max: 0.1
Current: -1.65

During the past 5 years, the highest EV-to-EBIT of NeuroSense Therapeutics was 0.10. The lowest was -8.75. And the median was 0.00.

NRSNW's EV-to-EBIT is ranked worse than
100% of 424 companies
in the Biotechnology industry
Industry Median: 9.96 vs NRSNW: -1.65

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. NeuroSense Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $0.00 Mil. NeuroSense Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.27 Mil. NeuroSense Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.

NeuroSense Therapeutics EV-to-EBIT Historical Data

The historical data trend for NeuroSense Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics EV-to-EBIT Chart

NeuroSense Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-3.92

-0.61

-0.85

NeuroSense Therapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial										-0.61	-1.21	-0.87	-0.54	-0.85

Competitive Comparison of NeuroSense Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, NeuroSense Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's EV-to-EBIT falls into.

NeuroSense Therapeutics EV-to-EBIT Calculation

NeuroSense Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/	-11.269
	=	0.00

NeuroSense Therapeutics's current Enterprise Value is $0.00 Mil.
NeuroSense Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.27 Mil.

NeuroSense Therapeutics (NAS:NRSNW) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

NeuroSense Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-11.269	/	0
	=	%

NeuroSense Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $0.00 Mil.
NeuroSense Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.27 Mil.

NeuroSense Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of NeuroSense Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSNW) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

NRSN:USA

Address

11 HaMenofim Street, Building B, Herzliya, ISR, 4676670

Website

https://www.neurosense-tx.com

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.